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Abstract
Background: Statins such as simvastatin are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase used in the prevention of cardiovascular disease. In addition to their cholesterol-lowering activities,
statins exert pleiotropic anti-inflammatory effects, which might contribute to their beneficial effects on lipid-
unrelated inflammatory diseases. Recently it has been demonstrated that the peroxisome proliferator-activated
receptor (PPAR)-a mediates anti-inflammatory effects of simvastatin in vivo models of acute inflammation.
Moreover, previous results suggest that PPAR-a plays a role in control of secondary inflammatory process
associated with spinal cord injury (SCI).
Methods: With the aim to characterize the role of PPAR-a in simvastatin activity, we tested the efficacy of
simvastatin (10 mg/kg dissolved in saline i.p. 1 h and 6 h after the trauma) in an experimental model of SCI
induced in mice by extradural compression of the spinal cord (T6-T7 level) using an aneurysm clip with a closing
force of 24 g via a four-level T5-T8 laminectomy, and comparing mice lacking PPAR-a (PPAR-a KO) with wild type
(WT) mice. In order to elucidate whether the effects of simvastatin are due to activation of the PPAR-a, we also
investigated the effect of a PPAR-a antagonist, GW6471 (1 mg/kg administered i.p. 30 min prior treatment with
simvastatin) on the protective effects of on simvastatin.
Results: Results indicate that simvastatin activity is weakened in PPAR-a KO mice, as compared to WT controls. In
particular, simvastatin was less effective in PPAR-a KO, compared to WT mice, as evaluated by inhibition of the degree
of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression,
nuclear factor (NF)-B activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. In addition we
demonstrated that GW6471 significantly antagonized the effect of the statin and thus abolished the protective effect.
Conclusions: This study indicates that PPAR-a can contribute to the anti-inflammatory activity of simvastatin in SCI.
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Introduction
Spinal cord injury (SCI) is the result of an initial physical
trauma followed by a secondary degenerative process.
SCI leads to the destruction of ascending and descending
axonal tracts that control motor, sensory and autonomic
functions. The level of SCI is an important factor because
the consequences are devastating. Patients suffer from
permanent, often lifelong motor and sensory disabilities
below the site of injury, combined with impaired basic
vital functions. Functional recovery is restricted because
axons in the central nervous system (CNS) regenerate
poorly. Post-traumatic inflammatory reaction may play
an important role in the secondary injury processes after
SCI [1,2].
In particular the secondary damage is determined by a
large number of cellular, molecular, and biochemical
cascades and a large body of data suggests the presence
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of a local inflammatory response, which amplifies the
secondary damage [3].
The contemporary management of SCI consists of
supportive care and stabilization of the spine [4].
Numerous pharmacologic therapies have been evaluated
for the treatment of SCI, although none have met with
substantial success.
Statins, such as simvastatin, are lipid-lowering drugs
that inhibit 3-hydroxy-3-methylglutaryl co-enzyme A
(HMG-CoA) reductase. They are widely prescribed cho-
lesterol-lowering drugs and are the first-line treatment
for the prevention of coronary artery disease and athero-
sclerosis [5]. Simvastatin have been shown to exhibit
important immunomodulatory and anti-inflammatory
effects independent of lipid lowering [6,7]. Statins have
pleiotropic effects on endothelium, platelets, smooth
muscle cells and inflammation. These effects included
the improvement of endothelial and microvascular func-
tion, the reduction of inflammation through decreased
expression of pro-inflammatory transcriptional factors
such as Nuclear Factor (NF)-B that in turn decreases
cytokines, chemokines and nitric oxide synthase (iNOS)
expression [8]. In particular, previous studies have shown
that simvastatin inhibits nitric oxide (NO) production
through a reduction of iNOS in a model of endotoxic
shock in rats [9].
Moreover, a large and growing body of evidences also
suggest beneficial therapeutic activities of statins in
immune and inflammatory diseases such as multiple
sclerosis, Alzheimer’s disease, ischemic stroke, transplant
rejection, rheumatoid arthritis, and asthma [10,11]. Several
clinical observations indicate that these effects cannot be
attributed to their cholesterol-lowering activities [12].
Peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear hormone receptor superfam-
ily of ligand-activated transcription factors [13]. PPARs
regulate target gene expression by binding as heterodi-
mers with retinoid × receptors (RXRs) to specific peroxi-
some proliferator response elements (PPREs) in enhancer
sites of regulated genes of DNA. The PPAR subfamily
comprises three members, PPAR-a PPAR-b and PPAR-g
[14]. RXRs are also members of the nuclear hormone
receptor superfamily that are activated by binding of
9-cis retinoic acid [15]. In the absence of a ligand, high
affinity complexes are formed between the PPAR-RXR
heterodimer and nuclear receptor co-repressor proteins,
preventing transcriptional activation by sequestration of
the nuclear receptor heterodimer from the promoter.
Binding of a ligand to the heterodimer results in the
release of the co-repressor from the complex, which in
turn results in the binding of the activated heterodimer
to the response element in the promoter region of the
relevant target genes, resulting in either the activation or
suppression of a specific gene [15,16].
In rats, PPAR-a is most highly expressed in brown
adipose tissue, followed by liver, kidney, heart and skele-
tal muscle [17]. The presence of PPAR-a in discrete
areas of brain and spinal cord has been suggested [18],
although its role remains unknown.
PPAR-a binds to a diverse set of ligands, namely, arachi-
donic acid metabolites (prostaglandins and leukotrienes)
and plasticizers and synthetic fibrate drugs including clofi-
brate, fenofibrate and bezafibrate [19]. Given that no single
high affinity natural ligand has been identified for PPAR-a,
it has been proposed that a physiological role of the recep-
tor may be to sense the total flux of dietary fatty acids in
key tissues. Many PPAR-a ligands, including most of the
common fibrate ligands, show only modest selectivity over
the other PPAR subtypes. However, a potent thioisobuty-
ric acid GW7647 has been identified that shows excellent
selectivity for both murine and human PPAR-a [20].
Various lines of evidence suggest that the activation of
PPAR-a by synthetic agonists causes marked anti-inflam-
matory effects in experimental models [21-23]. Indeed, we
have recently demonstrated using PPAR-a knock-out
(PPAR-aKO) mice that endogenous PPAR-a activity
reduces the degree of development of inflammation and
tissue injury events associated with spinal cord trauma in
mice, suggesting the existence of an intrinsic anti-inflam-
matory mechanism mediated by PPAR-a [24]. In addition,
it has been reported that PPAR-a activation can result in
inhibition of NF-B activation and inflammatory genes
expression [25-27].
Moreover, recently, Paumelle and colleagues have
clearly demonstrated that the acute anti-inflammatory
effect of simvastatin occurs via PPAR-a by a mechanism
involving inhibition of PKC-a inactivation of PPAR-a
transrepression activity [28].
To characterize the role of PPAR-a in statins-mediated
anti-inflammatory activity, we tested the efficacy of sim-
vastatin in an experimental model of spinal cord trauma
induced in mice by the application of vascular clips (force
of 24 g) to the dura via a four-level T5-T8 laminectomy,
comparing PPAR-aKO and WT mice.
Methods
Animals
Mice (6 weeks old, 20-22 g) with a targeted disruption of
the PPAR-a gene (PPAR-aKO) and littermate wild-type
controls (PPAR-aWT) were purchased from Jackson
Laboratories (Harlan Nossan, Italy). Mice homozygous
for the PparatniJGonz targeted mutation mice are viable,
fertile and appear normal in appearance and behaviour.
Exon eight, encoding the ligand-binding domain, was dis-
rupted by the insertion of a 1.14 kb neomycin resistance
gene in the opposite transcriptional direction. After elec-
troporation of the targeting construct into J1 ES cells, the
ES cells were injected into C57BL/6N blastocysts. This
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stain was created on B6,129S4 background and is main-
tained as a homozygote on a 129S4/SvJae background by
brother sister mating. The animals were housed in a con-
trolled environment and provided with standard rodent
chow and water. The study was approved by the Univer-
sity of Messina Animal Care Review Board. Animal care
was in compliance with Italian regulations on protection
of animals used for experimental and other scientific pur-
poses (D.M. 116192) as well as with the EEC regulations
(O.J. of E.C. L 358/1 12/18/1986).
SCI
Mice were anaesthetized using chloral hydrate (40 μg/kg
body weight). A longitudinal incision was made on the
midline of the back, exposing the paravertebral muscles.
These muscles were dissected away exposing T5-T8
vertebrae. The spinal cord was exposed via a four-level
T5-T8 laminectomy and SCI was produced by extradural
compression of the spinal cord (T6-T7) using an aneur-
ysm clip with a closing force of 24 g as previously
described [24]. Following surgery, 1 ml of saline was admi-
nistered subcutaneously in order to replace the blood
volume lost during surgery. During the surgery and the
recovery from anaesthesia, the mice were placed on a
warm heating pad and covered with a warm towel. The
mice were singly housed in a temperature-controlled
room at 27°C for a survival period of 10 days. Food and
water were provided to the mice ad libitum. During this
time period, the animals’ bladders were manually voided
twice a day until the mice were able to regain normal blad-
der function. In all injured groups, the spinal cord was
compressed for 1 min. Sham injured animals were only
subjected to laminectomy.
Experimental groups
Mice were randomly allocated into the following groups
(i) PPAR-aWT SCI group. WT mice were subjected to SCI
(N = 30); (ii) PPAR-aKO SCI group. PPAR-aKO mice
were subjected to SCI (N = 30); (iii) PPAR-aWT SCI+1 h
and 6 h after SCI Simvastatin group. Identical to the
PPAR-aWT SCI group but simvastatin (10 mg/kg dis-
solved in saline i.p. bolus) was administered as an intraper-
itoneal (i.p.) injection at 1 h and 6 h after SCI (N = 30); (iv)
PPAR-aKO simvastatin group. Identical to the PPAR-aKO
SCI group but simvastatin (10 mg/kg dissolved in saline
i.p. bolus) which was administered as an i.p. injection
starting 1 h and 6 h after SCI (N = 30); (v) PPAR-aWT
Sham + saline group. Mice were subjected to the surgical
procedures as above group except that the aneurysm clip
was not applied (N = 30); (vi) PPAR-aKO Sham + saline
group. Mice were subjected to the surgical procedures as
above group except that the aneurysm clip was not applied
(N = 30); (vii) PPAR-aWT Sham + simvastatin group.
Identical to PPAR-aWT Sham+saline group except for the
administration of simvastatin (N = 30); (viii) PPAR-aKO
Sham + simvastatin group. Identical to PPAR-aKO Sham
+saline group except for the administration of simvastatin
(N = 30); (ix) PPAR-aWT SCI + GW6471 group. Identical
to the PPAR-aWT SCI group but GW6471 was adminis-
tered (1 mg/kg i.p. bolus) 30 min, and 5 hours and 30 min
after SCI (N = 30); (x) PPAR-aWT SCI + GW6471 + Sim-
vastatin group. Identical to the PPAR-aWT Simvastatin
group, but GW6471 was administered (1 mg/kg i.p. bolus)
30 min prior to simvastatin. The doses of simvastatin
(10 mg/kg) and GW6471 (1 mg/kg) were chosen in agree-
ment with previous studies [29,30].
Light microscopy
Spinal cord tissues from perilesional zone were taken at
24 h following trauma. Tissue segments containing the
lesion (1 cm on each side of the lesion) were paraffin
embedded and cut into 5-μm-thick sections. The tissue
segments were fixed for 24 h in paraformaldehyde solution
(4% in PBS 0.1 M) at room temperature, dehydrated by
graded ethanol and embedded in Paraplast (Sherwood
Medical, Mahwah, NJ). Tissue sections were deparaffinized
with xylene, stained with Haematoxylin/Eosin (H&E) and
Luxol Fast Blue staining (used to assess demyelination)
and studied using light microscopy connected to an
Imaging system (AxioVision, Zeiss, Milan, Italy).
The histopathological changes of the gray matter were
scored on a 6-point scale: 0, no lesion observed, 1, gray
matter contained 1 to 5 eosinophilic neurons; 2, gray mat-
ter contained 5 to 10 eosinophilic neurons; 3, gray matter
contained more than 10 eosinophilic neurons; 4, small
infarction (less than one third of the gray matter area); 5,
moderate infarction; (one third to one half of the gray
matter area); 6, large infarction (more than half of the gray
matter area). The scores from all the sections from each
spinal cord were averaged to give a final score for indivi-
dual mice. All the histological studies were performed in a
blinded fashion.
Terminal Deoxynucleotidyltransferase-Mediated UTP End
Labelling (TUNEL) Assay
TUNEL assay was conducted by using a TUNEL detec-
tion kit according to the manufacturer’s instruction
(Apotag, HRP kit DBA, Milan, Italy). Briefly, sections
were incubated with 15 μg/ml proteinase K for 15 min at
room temperature and then washed with PBS. Endogen-
ous peroxidase was inactivated by 3% H2O2 for 5 min at
room temperature and then washed with PBS. Sections
were immersed in terminal deoxynucleotidyltransferase
(TdT) buffer containing deoxynucleotidyl transferase and
biotinylated dUTP in TdT buffer, incubated in a humid
atmosphere at 37°C for 90 min, and then washed with
PBS. The sections were incubated at room temperature
for 30 min with anti-horseradish peroxidase-conjugated
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antibody, and the signals were visualized with diamino-
benzidine. The number of TUNEL positive cells/high-
power field was counted in 5 to 10 fields for each coded
slide.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity, an indicator of poly-
morphonuclear leukocyte (PMN) accumulation, was
determined as previously described [31]. At the specified
time following SCI, spinal cord tissues were obtained and
weighed, each piece homogenized in a solution contain-
ing 0.5% (w/v) hexadecyltrimethyl-ammonium bromide
dissolved in 10 mM potassium phosphate buffer (pH 7)
and centrifuged for 30 min at 20,000 × g at 4°C. An ali-
quot of the supernatant was then allowed to react with a
solution of tetramethylbenzidine (1.6 mM) and 0.1 mM
hydrogen peroxide. The rate of change in absorbance was
measured spectrophotometrically at 650 nm. MPO activ-
ity was defined as the quantity of enzyme degrading
1 μmol of peroxide/min at 37°C and was expressed in
units per g of wet tissue.
Grading of motor disturbance
The motor function of mice subjected to compression
trauma was assessed once a day for 10 days after injury.
Recovery from motor disturbance was graded using the
Basso Mouse Scale (BMS) [32].
Measurement of Tumor Necrosis Factor-a and
Interleuchin (IL)-1b concentration
Portions of spinal cord tissues from perilesional zone, col-
lected 24 h after SCI, were homogenized in PBS contain-
ing 2 mmol/L of PMSF (Sigma Chemical Co.), and tissue
TNF-a and IL-1b levels were evaluated. The assay was
carried out by using a colorimetric, commercial kit (Quan-
tikine R&D System, USA) according to the manufacturer
instructions. All TNF-a and IL-1b determinations were
performed in duplicate serial dilutions.
Localization of nitrotyrosine, TNF-a, Bax, iNOS, Bcl-2, Fas-
ligand, nitrotyrosine, by immunohistochemistry
At the 24th hour after SCI, the tissues were fixed in 10%
(w/v) PBS-buffered formaldehyde and 5 μm sections
were prepared from paraffin embedded tissues. After
deparaffinization, endogenous peroxidase was quenched
with 0.3% H2O2 in 60% methanol for 30 min. The sec-
tions were permeabilized with 0.1% Triton X-100 in PBS
for 20 min. Non-specific adsorption was minimized by
incubating the section in 2% normal goat serum in PBS
for 20 min. Endogenous biotin or avidin binding sites
were blocked by sequential incubation for 15 min with
avidin and biotin (DBA, Milan, Italy). Sections were incu-
bated overnight with anti-nitrotyrosine antibody (1:500
in PBS, Upstate), with anti-Bax antibody (1:500 in PBS,
Santa Cruz Biotechnology) with anti-TNF-a polyclonal
antibody (1:100 in PBS, Santa Cruz Biotechnology) with
anti-iNOS (1:500 in PBS, Transduction Laboratories), or
with anti-Bcl-2 antibody (1:100 in PBS, Santa Cruz Bio-
technology), with anti-Fas-ligand antibody (1:100 in PBS,
Abcam). Specific labelling was detected with a biotin-
conjugated goat anti-rabbit, donkey anti-goat or goat
anti-mouse IgG and avidin-biotin peroxidase complex
(DBA, Milan, Italy). To verify the binding specificity for
Bax, Bcl-2, iNOS, Fas-ligand, TNF-a or nitrotyrosine,
some sections were also incubated with primary antibody
only (no secondary antibody) or with secondary antibody
only (no primary antibody). In these situations, no posi-
tive staining was found in the sections indicating that the
immunoreactions were positive in all the experiments
carried out.
Immunocytochemistry photographs (N = 5) were
assessed by densitometry as previously described [33] by
using Imaging Densitometer (AxioVision, Zeiss, Milan,
Italy) and a computer program. In particular the densito-
metry analysis was carried out in section in which the
spinal cord tissues were orientated longitudinally in order
to observe all the histological portions.
Nuclear and cytoplasm protein extraction
Spinal cord Tissues from perilesional zone were obtained
from the animals of all experimental groups were homoge-
nized on ice in ice-cold hypotonic buffer A (10 mM Hepes
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT, 0.5 mM PMSF with a protease inhibitor
cocktail) using a Politron PT 13,000 D tissue homogenizer
(Kinematica). After 15 min incubation on ice, the homoge-
nates were centrifuged at 1,000 g for 10 min at 4°C. Super-
natants containing cytoplasm extracts were stored at
-80°C. Nuclear pellets were resuspended in ice-cold buffer
B (1% Triton X-100, 150 mM NaCl, 10 mM TRIS-HCl pH
7.4, 1 mM EGTA, 1 mM EDTA, 0,2 mM PMSF, 20 mm
leupeptin, 0,2 mM sodium orthovanadate) and the tubes
were vigorously rocked at 4°C for 30 min on a shaking
platform. The nuclear extracts were centrifuged at
13,000 g for 15 min at 4°C. The supernatants were frozen
in aliquots at -80°C until use. Protein concentrations were
determined by the Bradford method using bovine serum
albumin (BSA) as standard [34].
NF-B nuclear translocation assessment and PPAR-a
expression by Western blot
Proteins from cytoplasm and nuclear fraction were added
to sample buffer [0.125 M Tris-HCl, (pH 6.8), 4% SDS,
20% glycerol, 10% b-mercaptoethanol, 0.004% bromphenol
blue], and boiled in a water bath for 5 min. Protein sam-
ples (40 μg per lane) were separated on denaturing 12%
SDS polyacrylamide gel and transferred to a nitrocellulose
membrane. Non-specific binding to the membrane was
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blocked for 1 h at room temperature with 5% milk in PBS.
Membranes were then incubated at 4°C overnight with
primary antibody in milk-PBS- Tween 20 0.1% (PMT) for
NF-B p65 (1:1000; Santa Cruz Biotechnology), PPAR-a,
(Santa Cruz Biotechnology, 1:500), and IB-a (1:1000;
Santa Cruz Biotechnology) in PMT, washed three times
with PBS -0.1% Tween, and then incubated for 1 h at
room temperature with a secondary antibody (peroxidase-
conjugated bovine anti-mouse IgG secondary antibody or
peroxidase-conjugated goat anti-rabbit IgG, 1:2000; Jack-
son ImmunoResearch, West Grove, PA). Polyclonal anti-
actin and anti-lamin A/C antibodies were used as an inter-
nal standard for cytoplasm and nuclear fractions, respec-
tively. The immunoreactive bands were visualized using an
enhanced chemilumunescence system (SuperSignal West
Femto Maximum Sensitivity Substrate, Pierce). The
protein bands were scanned and quantitated with Gel
Doc-2000 (Bio-Rad).
Reagents
Biotin blocking kit, biotin-conjugated goat anti-rabbit
IgG and avidin-biotin peroxidase complex were obtained
from Vector Laboratories (Burlingame, CA, USA).
Reagents and secondary and nonspecific IgG antibody for
immunohistochemical analysis were from Vector Labora-
tories InC. PPAR-alpha antagonist N-((2S)-2-(((1Z)-1-
Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)
amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)
ethoxy)phenyl)propyl)propanamide (GW6471) was pur-
chased by Tocris. All other reagents and compounds
used were obtained from Sigma Chemical Company.
Statistical analysis
All values in the figures and text are expressed as mean ±
standard error of the mean (SEM) of N observations. For
the in vivo studies N represents the number of animals
studied. In the experiments involving histology or immu-
nohistochemistry, the figures shown are representative of
at least three experiments performed on different experi-
mental days. The results were analyzed by one-way
ANOVA followed by a Bonferroni post-hoc test for multi-
ple comparisons. A p-value of less than 0.05 was consid-
ered significant. BMS scale data were analyzed by the
Mann-Whitney test and considered significant when p-
value was < 0.05.
Results
Effects of simvastatin treatment on PPAR-a expression in
spinal cord tissue
Previous studies have demonstrated an important role for
PPAR-a in SCI [35] and have suggested that the ability of
simvastatin to reduce inflammation is also dependent on
activation of PPAR-a [36,37]. Thus we evaluated PPAR-a
expression in the nuclear fractions from spinal cord tissue
by Western Blot analysis. A basal level of PPAR-a was
detected in spinal cord tissue from sham WT-simvastatin
treated mice, whereas SCI significantly reduced the levels
of PPAR-a in the spinal cords (**p < 0.01; Figure 1 panels
a and a1). Administration of simvastatin, 1 h and 6 h after
SCI, significantly reversed spinal cord PPAR-a levels
down-regulated by SCI (##p < 0.01), as determined by
densitometric analysis (Figure 1).
Role of functional PPAR-a gene in the anti-inflammatory
effect of simvastatin on the degree of spinal cord trauma
Twenty four hours after the trauma a significant damage
to the spinal cord from WT mice at the perilesional zone
was observed in H&E staining slices as assessed by the
presence of oedema as well as an alteration of the white
matter (Figure 2c and see histological score h) when com-
pared with spinal cord tissue collected from PPAR-a WT
(Figure 2a). No histological alteration was observed in
spinal cord tissue from vehicle-treated PPAR-aKO mice
(Figure 2b; see histological score h). Simvastatin treatment
resulted in a significant decrease in the extent and severity
of the histological signs of spinal cord trauma (Figure 2d
and see histological score h). The absence of PPAR-a gene
Figure 1 PPAR-a expression in spinal cord tissues. A basal level
of PPAR-a was detected in the spinal cord tissues from shamWT-
operated mice, whereas in SCI-operated PPARaWT mice the levels
were substantially reduced (panels A and A1). Simvastatin
treatment significantly reversed the spinal PPAR-a levels down-
regulated by SCI (panels A and A1). The relative expression of the
protein bands was standardized for densitometric analysis to lamin
levels, reported in panel a1, and expressed as mean ± s.e.m. from n
= 5/6 spinal cord for each group. *P < 0.01 versus sham, °P < 0.01
versus SCI+vehicle.
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Figure 2 Effect of PPAR-a on the anti-inflammatory property of simvastatin on the degree of SCI. No histological alterations have been
found in the spinal cord tissue collected from PPAR-a WT or PPAR-a KO sham-operated mice (a,b and histological score h). A significant
damage to the spinal cord from PPAR-aWT mice at the perilesional zone was observed from H&E staining (c see histological score h). The
treatment of PPAR-aWT with simvastatin resulted in a significant decrease in the extent and severity of the histological signs (d, and histological
score h). The absence of PPAR-a gene significantly increases the extent and severity of the histological signs (e, and histological score h). The
genetic absence of the PPAR-a receptor (f) as well as the treatment with GW6471 (g) significantly blocked the effect of the simvastatin
treatment (histological score h). Data are means ± SEM of 10 mice for each group. *P < 0.01 vs. Sham; °P < 0.01 vs. SCI-WT group; ‡P < 0.01 vs.
simvastatin -treated -WT group. ND: not detectable.
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significantly increases the extent and severity of trauma in
the spinal cord tissue (Figure 2e see histological score h).
The genetic absence of the PPAR-a significantly blocked
the effect of the simvastatin treatment (Figure 2f see histo-
logical score h). Moreover, treatment with the PPAR-a
antagonist GW6471 (1 mg/kg) blocked simvastatin-
mediated neuroprotection (Figure 2g, see histological
score h).
In order to evaluate if histological damage to the
spinal cord was associated a loss of motor function the
BMS hind limb locomotor rating scale score was
evaluated (Figure 3a). While motor function was not
impaired in sham mice (data not shown), PPAR-a WT
mice undergoing SCI had significant deficits in hind
limb movement (Figure 3a). In contrast, a significant
worsened of hind limb motor disturbances was observed
in PPAR-aKO operated mice (Figure 3a). The treatment
of PPAR-a WT with simvastatin resulted in a significant
recovery of motor function (Figure 3a). The genetic
absence of the PPAR-a significantly blocked also the
effect of the simvastatin treatment on improvement of
motor function (Figure 3a).
Figure 3 Role of PPAR-a in simvastatin-induced recovery of motor function and inhibition of neutrophil infiltration after SCI. To
evaluate if histological damage to the spinal cord was associated a loss of motor function the modified BMS hind limb locomotor rating scale
score was evaluated (a). The degree of motor disturbance was assessed every day until 10 days after SCI by BMS criteria. Treatment of injured-
PPAR-a WT mice with simvastatin significantly reduces the motor disturbance after SCI (a). In addition, we investigate the role of simvastatin on
the neutrophil infiltration by measurement of the activity of MPO. Treatment with simvastatin significantly reduced the MPO activity (h). The
genetic absence of the PPAR-a as well as the treatment with GW6471 significantly blocked the effect of simvastatin treatment on motor
recovery (a) and neutrophils infiltration (b). Data are means ± SEM of 10 mice for each group. *P < 0.01 vs. Sham; °P < 0.01 vs. SCI-WT group; ‡P
< 0.01 vs. simvastatin -treated WT mice.
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In addition, in order to evaluate that the protective
effects of simvastatin on the severity of spinal cord trauma
are due to agonistic actions on the PPAR-a receptor, we
have also investigated the effect of GW6471, a PPAR-a
antagonist. Co-administration of GW6471 and simvastatin
significantly blocked the effect of the statin on tissue injury
(Figure 1g see histological score h) and motor function
impairment (Figure 3a) induced by SCI.
Role of PPAR-a in simvastatin-induced inhibition of PMN
infiltration
The above histological pattern of spinal cord injury
appeared to be correlated with the influx of leukocytes
into the spinal cord. Therefore, we investigate the role of
PPAR-a ligand on the neutrophils infiltration by measure-
ment of the activity MPO. MPO activity was significantly
elevated (p < 0.001) at 24th hour after SCI in PPAR-aWT
mice (Figure 3b). In PPAR-aKO mice following SCI spinal
cord MPO activity was significantly enhanced (p < 0.01) in
comparison to those of WT animals (Figure 3b). On the
contrary, simvastatin significantly reduced the degree of
PMN infiltration (determined as increase in MPO activity)
in spinal cord tissues collected at 24th hour after SCI in
WT mice (Figure 3b). The genetic absence of the PPAR-a
receptor as well as the treatment with GW6471, a PPAR-a
antagonist significantly blocked the effect of the simvasta-
tin on the neutrophils infiltration (Figure 3b).
Role of PPAR-a in simvastatin-induced inhibition of tnf-a
and il-1b after spinal cord trauma
Release of pro-inflammatory cytokines is an important
mechanism responsible for spinal cord trauma. A substan-
tial increase in TNF-a and IL-1b formation was found in
spinal cord tissues collected from WT mice at 24 h after
SCI (Figure 4h, i). Spinal cord levels of TNF-a and IL-1b
were significantly higher in PPAR-a deficient mice in
comparison to those of WT animals (Figure 4h, i). In con-
trast a significant inhibition of TNF-a and IL-1b levels
was observed in the spinal cord tissues collected from of
WT mice treated with simvastatin (Figure 4h, i). The
genetic absence of the PPAR-a receptor significantly
blocked the effect of the simvastatin on the production of
pro-inflammatory cytokines (Figure 4h, i). In addition, tis-
sue sections obtained from WT animals at 24 h after SCI
demonstrate positive staining for TNF-a (Figure 4b see
densitometry analysis g) mainly localized in inflammatory
cells as well as in nuclei of Schwann cells in the white and
gray matter of the spinal cord tissues. In SCI-injured
PPAR-aKO mice, the staining for TNF-a was visibly and
significantly increased in comparison with the WT mice
(Figure 4e and see densitometry analysis g). Section from
simvastatin-treated PPAR-aWT mice did not reveal posi-
tive staining TNF-a (Figure 4c and see densitometry ana-
lysis g). The genetic absence of the PPAR-a receptor
significantly blocked the effect of simvastatin on the TNF-
a expression (Figure 4f and see densitometry analysis g).
Sections of spinal cord tissues from sham-administered
PPAR-a mice did not stain for TNF-a (Figure 4a, d and
see densitometry analysis g).
Role of PPAR-a in simvastatin-induced inhibition of iNOS
expression
Spinal cord sections from sham PPAR-a mice did not stain
for iNOS (Figure 5Aa, Ad and see densitometry analysis
Ag). Spinal cord sections obtained from vehicle-treated
SCI-PPAR-aWT mice exhibited positive staining for iNOS
(Figure 5Ab and see densitometry analysis Ag) mainly loca-
lized in inflammatory cells as well as in nuclei of Schwann
cells in the white and gray matter of the spinal cord tissues.
In SCI-injured PPAR-aKO mice, the staining for iNOS was
visibly and significantly increased (Figure 5Ae and see den-
sitometry analysis Ag) in comparison with the PPAR-aWT
mice. Section from simvastatin-treated WT mice did not
reveal any positive staining for iNOS (Figure 5Ac and see
densitometry analysis Ag). The genetic absence of the
PPAR-a receptor significantly blocked the effect of the sim-
vastatin on iNOS expression (Figure 5Af and see densito-
metry analysis Ag).
Role of PPAR-a in simvastatin-induced inhibition of
nitrotyrosine formation
To determine the localization of “peroxynitrite formation”
and/or other nitrogen derivatives produced after SCI,
nitrotyrosine, a specific marker of nitrosative stress, was
measured by immunohistochemical analysis in the spinal
cord tissues. Sections of spinal cord from sham PPAR-a
mice did not stain for nitrotyrosine (Figure 5Ba, Bd and
see densitometry analysis Bg). Spinal cord sections
obtained from vehicle-treated SCI-WT mice exhibited
positive staining for nitrotyrosine (Figure 5Bb, and see
densitometry analysis Bg) mainly localized in inflammatory
cells as well as in nuclei of Schwann cells in the white and
gray matter of the spinal cord tissues. In SCI-injured
PPAR-aKO mice, the staining for nitrotyrosine was visibly
increased (Figure 5Be and see densitometry analysis Bg) in
comparison with the PPAR-aWT mice. Section from sim-
vastatin-treated WT mice did not reveal any positive stain-
ing for nitrotyrosine (Figure 5Bc, and see densitometry
analysis Bg). The genetic absence of the PPAR-a receptor
significantly blocked the effect of the simvastatin on nitro-
tyrosine formation (Figure 5Bf and see densitometry analy-
sis Bg).
Role of PPAR-a in simvastatin-induced inhibition of Fas-
ligand expression
Sections of spinal cord from sham PPAR-a mice did not
stain for Fas-ligand (Figure 6Aa, Ad and see densitome-
try analysis Ag). Spinal cord sections obtained from
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vehicle-treated SCI-WT mice exhibited positive staining
for Fas-ligand (Figure 6Ab, see densitometry analysis
Ag) mainly localized in inflammatory cells as well as in
nuclei of Schwann cells in the white and gray matter of
the spinal cord tissues. In SCI-injured PPAR-aKO mice,
the staining for Fas-ligand was visibly and significantly
increased (Figure 6Ae, see densitometry analysis Ag) in
comparison with WT mice. Section from simvastatin-
treated WT mice did not reveal any positive staining for
Fas-ligand (Figure 6Ac, see densitometry analysis Ag).
The genetic absence of the PPAR-a receptor signifi-
cantly blocked the effect of the simvastatin on Fas-
ligand expression (Figure 6Af, see densitometry analysis
Ag).
Role of PPAR-a in simvastatin-induced inhibition on
apoptosis
To test whether the tissue damage was associated with
cell death by apoptosis, we measured TUNEL-like stain-
ing in the injured tissue. Almost no apoptotic cells were
Figure 4 Role of PPAR-a in simvastatin-induced inhibition of TNF-a and IL-1b after SCI WT mice show a significant production of
cytokines at 24 hours after SCI (h, i). Cytokine levels were significantly enhanced in injured-PPAR-a KO mice (h, i). Treatment with simvastatin
significantly reduced the spinal cord TNF-a and IL-1b (i) production. The genetic absence of the PPAR-a receptor significantly blocked the effect
of simvastatin treatment (h, i). Data are means ±S.E. mean of 10 mice for each group. *P < 0.01 vs. Sham; °P < 0.01 vs. SCI-WT group; °°P < 0.01
vs. simvastatin-treated WT group. In addition, tissue sections obtained from PPAR-aWT animals at 24 h after SCI demonstrate positive staining for
TNF-a when compared with spinal cord tissue collected from PPAR-a sham-operated mice (a, d and g) The intensity of the positive staining for
TNF-a was markedly increased in tissue section from injured-PPAR-aKO mice (e, g). Section from simvastatin-treated PPAR-aWT mice did not
reveal positive staining for TNF-a (c, g) The genetic absence of the PPAR-a significantly blocked the effect of simvastatin on the TNF-a
expression (f, g). Data are means ± SEM of 10 mice for each group. The assay was carried out by using Imaging Densitometer (AxioVision, Zeiss,
Milan, Italy). Data are expressed as % of total tissue area. This figure is representative of at least 3 experiments performed on different
experimental days. *P < 0.01 vs. Sham; °P < 0.01 vs. SCI-WT group; °°P < 0.01 vs. simvastatin-treated WT mice. ND: not detectable.
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detected in the spinal cord sections from sham PPAR-a
mice (Figure 6Ba, Bd see number of TUNEL positive
cells Bg). In addition, tissue sections obtained from WT
animals at 24h after SCI demonstrate a marked appear-
ance of dark brown apoptotic cells and intercellular
apoptotic fragments (Figure 6Bb, see number of TUNEL
positive cells Bg). In SCI-injured PPAR-aKO mice, the
presence of apoptotic cell (Figure 6Be, see number of
TUNEL positive cells Bg) was visibly and significantly
increased in comparison with the PPAR-aWT mice. No
apoptotic cells were observed in the section from
simvastatin-treated PPAR-aWT mice (Figure 6Bc, see
number of TUNEL positive cells Bg). The genetic
absence of the PPAR-a receptor significantly blocked
the effect of simvastatin (Figure 6Bf, see number of
TUNEL positive cells Bg).
Immunohistochemistry for Bax and Bcl-2
Samples of spinal cord tissue were taken at 24 h after SCI
in order to determine the immunohistological staining
for apoptotic protein family. Sections of spinal cord from
sham PPAR-a mice did not stain for Bax (Figure 7Aa, Ad
Figure 5 Role of PPAR-a in simvastatin-induced inhibition on iNOS expression and on nitrotyrosine formation. Spinal cord from sham
PPAR-aWT mice did not stain for iNOS (panel A a, d and g). Spinal cord sections from injured-PPAR-a WT and from injured-PPAR-a mice (panel
A e, g) exhibited positive staining for iNOS (panel A b, g); section from simvastatin-treated PPAR-aWT SCI mice did not reveal any positive
staining for iNOS (panel A c, g). The genetic absence of the PPAR-a significantly blocked the effect of the simvastatin on iNOS expression (panel
A f, g). In addition, immunohistochemical analysis for nitrotyrosine show positive staining localized in the inflammatory cells in the injured area
from SCI-PPAR-aWT mice (panel B b, g). The intensity of the positive staining for nitrotyrosine was markedly increased in tissue section obtained
from injured-PPAR-aKO mice (panel B e, g). No positive staining for nitrotyrosine was observed in tissue section from simvastatin-treated PPAR-
aWT mice (panel B c, g). The genetic absence of the PPAR-a significantly blocked the effect of simvastatin treatment (panel B f, g). Densitometry
analysis of immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each experimental group) for iNOS
(panel A, g) and nitrotyrosine (panel B, g) was assessed. The assay was carried out by using Imaging Densitometer (AxioVision, Zeiss, Milan, Italy).
Data are expressed as % of total tissue area. This figure is representative of at least 3 experiments performed on different experimental days. *P
< 0.01 vs. Sham; °P < 0.01 vs. SCI-WT group; °°P < 0.01 vs. simvastatin-treated WT group. ND: not detectable.
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and see densitometry analysis g) whereas spinal cord tis-
sue sections obtained from SCI- WT mice exhibited a
positive staining for Bax (Figure 7 Ab, see densitometry
analysis g). In SCI-injured PPAR-aKO mice, the staining
for Bax was visibly and significantly increased (Figure
7Ae, see densitometry analysis g) in comparison with the
PPAR-aWT mice. Section from simvastatin-treated
PPAR-aWT mice did not reveal any positive staining for
Bax (Figure 7Ac, see densitometry analysis g). The
genetic absence of the PPAR-a receptor significantly
blocked the effect of the simvastatin on Bax expression
(Figure 7Af, see densitometry analysis g).
In addition, spinal cord sections from sham WT
PPAR-a mice demonstrated Bcl-2 positive staining (Fig-
ure 7Ba, Bd and see densitometry analysis g) while in
spinal cord tissue sections obtained from SCI-WT mice
the staining for Bcl-2 were significantly reduced (Figure
7Bb, see densitometry analysis g). In SCI-PPAR-aKO
mice, the loss of staining for Bcl-2 was visibly and sig-
nificantly increased (Figure 7Be, see densitometry
Figure 6 Immunohistochemical localization of Fas-ligand and TUNEL staining in the spinal cord tissue. Immunohistochemical analysis for
Fas-ligand show positive staining localized in the inflammatory cells in the injured area from PPAR-aWT mice (panel A b, g). The intensity of the
positive staining for Fas-ligand was markedly increased in tissue section obtained from injured-PPAR-aKO mice (panel A e, g). No positive
staining for Fas-ligand was observed in tissue section from simvastatin-treated PPAR-aWT mice (panel A c, g). The genetic absence of the PPAR-
a significantly blocked the effect of simvastatin treatment (panel A f, g). To test whether the tissue damage was associated with cell death by
apoptosis, we measured TUNEL-like staining in the injured tissue. No apoptotic cells were detected in the spinal cord from sham-PPAR-aWT
mice (panel B a, d and g). Tissue sections from PPAR-aWT animals at 24 h after SCI demonstrate a marked appearance of dark brown apoptotic
cells (panel B b, g). Tissue sections from PPAR-aKO animals at 24 h after SCI demonstrate a marked appearance of dark brown apoptotic cells
(panel B b, g). The genetic absence of the PPAR-a receptor significantly blocked the effect of simvastatin (panel B f, g). Densitometry analysis of
immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each experimental group) for Fas-ligand from
spinal cord tissues was assessed. Data are expressed as % of total tissue area. This figure is representative of at least 3 experiments performed on
different experimental days. *P < 0.01 vs. Sham; °P < 0.01 vs. SCI-WT group; °°P < 0.01 vs. simvastatin-treated WT group. ND: not detectable.
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analysis g) in comparison with the WT mice. The loss of
positive staining for Bcl-2 was significant attenuated in
the spinal cord tissues from simvastatin-treated PPAR-
aWT mice (Figure 7Bc, see densitometry analysis g).
The genetic absence of the PPAR-a receptor signifi-
cantly blocked the effect of the simvastatin on the loss
of Bcl-2 staining (Figure 7Bf, see densitometry analysis
g).
Role of PPAR-a in simvastatin-mediated inhibition of SCI-
induced NF-B activation
Most inflammatory mediators, including iNOS, COX-2,
IL-1b and TNF-a are controlled by NF-B, a transcrip-
tion factor important in inflammatory process, which is
kept inactive by IB [38-40]. Moreover, activation of
NF-B transactivation potential is increased by phos-
phorylation of the p65 subunit [41]. We performed
experiments to evaluate the possible effect of simvastatin
on SCI-induced NF-B potential activation in WT and
PPAR-aKO mice at twenty-four hours after trauma.
In sham groups there were no significant differences
after simvastatin treatment between PPAR-aWT and
PPAR-aKO mice. On the other hand in SCI groups
there was a significant reduction of cytoplasmatic IB-a
expression compared to sham groups.
In untreated SCI mice, IB-a levels were significantly
reduced in PPAR-aKO mice respect to PPAR-aWT
mice (Figure 8a). Simvastatin administration prevented
the SCI-induced IB-a degradation in PPAR-aWT mice
while in PPAR-aKO the statin could not prevent IB-a
degradation (Figure 8a).
Moreover, NF-B p65 levels in the nuclear fractions
from spinal cord tissue were also significantly increased
in SCI groups compared to sham groups (Figure 8b).
After SCI untreated PPAR-a KO mice showed NF-B
levels higher than PPAR-aWT mice (Figure 8b). Simvas-
tatin treatment (10 mg/kg) significantly reduced the
SCI-induced NF-B activation in PPAR-aWT mice
more than in PPAR-aKO (Figure 8b). Therefore the
absence of PPAR-a gene interferes with the protective
effect of statin (Figure 8a, b).
Discussion
The CNS is sensitive to mechanical injuries causing per-
manent functional deficits such as the case of patients
who have SCI. The mechanical forces imparted to the
spinal cord cause immediate tissue disruption, with a
direct axonal and neuronal injury, inducing the death of
a number of neurons that cannot be recovered and
regenerated. Moreover, neurons continue to die for
hours after SCI due to several mechanisms including
excitotoxicity, vascular abnormalities and inflammatory
response that can contribute to evolution of spinal cord
secondary injury [42].
Post-traumatic inflammation is determined by a num-
ber of cellular and molecular events [43]. Leukocytes are
directly involved in the pathogenesis and extension of
SCI [43,44].
In the present paper we show that the absence of
PPAR-a gene, in PPAR-a KO mice, results in a reduced
anti-inflammatory response to simvastatin treatment in
an experimental model of SCI. These results are in
agreement with a previous observations indicating that
the acute anti-inflammatory effect of simvastatin occurs
via PPARa by a mechanism involving inhibition of
PKCa inactivation of PPARa transrepression activity
[28].
Clinical trials and in vitro studies have shown that sta-
tins and PPAR-a agonists share anti-inflammatory prop-
erties by regulating inflammatory-response genes
[45,46]. In particular, the in vivo anti-inflammatory
effects of simvastatin on footpad swelling and neutrophil
recruitment in air pouch-bearing mice already occur
within 1 hour after a single oral administration, indicat-
ing that the PPARa-dependent anti-inflammatory effects
of simvastatin occur rapidly [28].
PPAR-a is also able to directly mediate anti-inflamma-
tory effects and it has been shown that its agonist-
induced activation inhibits a number of inflammatory
mechanisms including TNF-a production, iNOS and
COX-2, adhesion molecules expression as well cell infil-
tration in the tissues [35,47].
Based on these observations we performed studies in
the attempt to determine whether the presence and/or
the stimulation of PPAR-a could enhance the simvasta-
tin anti-inflammatory efficacy. For that purpose we used
an experimental model of SCI induced by extradural
compression of the spinal cord (T6-T7) using an aneur-
ysm clip with a closing force of 24 g via a four-level T5-
T8 laminectomy, performed in WT and PPAR-aKO
mice.
There is a large body of evidence showing that the
production of reactive oxygen and nitrogen species play
key roles in the development of secondary neuronal
damage of SCI [48-52].
Not only peroxynitrite (ONOO-) was detected in
spinal cord tissues from rats following traumatic injury
[52,53], but ONOO- donor administration directly into
the rat spinal cord has been shown to cause neuronal
cell death and neurological deficits [48,49]. Previous
reports have demonstrated that ONOO- is toxic for neu-
rons in vitro [54] and recently it have been also estab-
lished that primary spinal cord neurons also undergo
cell death following ONOO- treatment [51]. ONOO- is
known to mediate several potentially destructive chemi-
cal reactions, including tyrosine nitration and lipid per-
oxidation [55,56]. Mitochondrial respiration is directly
inhibited by ONOO- and is an early marker of its
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cytotoxic effects [54,57]. Several antioxidants showed
neuroprotection in SCI and in associated conditions like
oxidative stress and inflammation [35,48,51].
In the present study we clearly demonstrate that when
WT and PPAR-aKO mice were treated with simvastatin
a significant inhibition of nitrotyrosine formation was
observed in WT but not in PPAR-aKO mice.
In addition, one consequence of increased oxidative
stress is the activation and inactivation of redox-sensi-
tive proteins [58]. Recent evidence suggests that the
activation of NF-B may also be under the control of
oxidant/antioxidant balance [59].
In the present study we demonstrated that PPARa
and simvastatin were synergic in negatively interfere
with the NF-B signalling transduction. In fact in spinal
cord tissues simvastatin treatment was able to signifi-
cantly reduce the NF-B activation. The important anti-
inflammatory role of PPARa was evident in PPARa
lacking mice where the NF-B activity was less reduced
compared to PPARaWT mice. These data confirmed
Figure 7 Immunohistochemistry for Bax and Bcl-2. Spinal cord tissue were taken in order to determine the immunohistological staining for
Bax and Bcl-2. Sections from sham PPAR-aWT mice did not stain for Bax (panel A a, d and g), whereas spinal cord tissue sections obtained from
SCI-PPAR-aWT mice exhibited a positive staining for Bax (panel A b, g). The intensity of the positive staining for Bax was markedly increased in
tissue section from injured-PPAR-aKO mice (panel A e, g). Spinal cord section from simvastatin-treated PPAR-aWT mice did not reveal any
positive staining for Bax (panel A c, g). The genetic absence of the PPAR-a receptor significantly blocked the effect of the simvastatin on Bax
expression (panel A f, g). In addition, spinal cord sections from sham-PPAR-aWT mice demonstrated Bcl-2 positive staining (panel B a, d and g),
while in spinal cord tissue sections obtained from SCI-PPAR-aWT (panel B b, g) and from SCI-PPAR-a mice (panel B e, g), the staining for Bcl-2
were significantly reduced. The loss of positive staining for Bcl-2 was significant attenuated in the spinal cord from simvastatin-treated PPAR-aWT
mice (panel B c, g). The genetic absence of the PPAR-a significantly blocked the effect of the simvastatin on the loss of Bcl-2 staining (panel B f,
g). Data are expressed as % of total tissue area. This figure is representative of at least 3 experiments performed on different experimental days.
*P < 0.01 vs. Sham; °P < 0.01 vs. SCI-WT group; °°P < 0.01 vs. simvastatin-treated WT group. ND: not detectable.
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our previous studies that explained the anti-inflamma-
tory effect of PPARa through an inhibition of NF-B
pathway [60,61]. There is evidence that production of
pro-inflammatory cytokines, such as TNF-a and IL-1b,
is important to induce local and systemic inflammation
and that production of this cytokine can be inhibited by
treatment with statin [28,62].
Benani and colleagues reported in a recent work [63]
that PPAR-a expression was less expressed in the gray
matter, while a high expression was observed in some
cells in the white matter, especially in astrocytes [63].
The presence of PPAR-a in astrocytes suggested at these
authors that this isoform modulates central inflamma-
tion, possibly by regulation of cytokine production by
astrocytes. This function of anti-inflammatory factor has
been demonstrated outside the CNS, as an inflammation
induced by leukotriene B4, a natural inflammation med-
iator, was prolonged in PPAR-a null mice as compared
to control animals [64,65]. In the present study we
demonstrate that when WT and PPAR-aKO mice were
treated with simvastatin a significant inhibition of TNF-a
and IL-1b level was measured in WT but not in PPAR-
aKO mice.
NF-B activation is crucially involved in Fas-Ligand
expression induced by DNA-damaging agents, such as
genotoxic drugs and ultraviolet (UV) radiation [66]. FasL
plays a central role in apoptosis induced by a variety of
chemical and physical insults [67]. Recently, it has been
pointed out that FasL signalling plays a central role in
spinal cord injury [68] and cell death induced by reactive
oxygen species (ROS) depends on FasL expression
mediated by redox sensitive activation of NF-B [69]. We
confirm here that SCI leads to a substantial activation of
FasL in the spinal cord tissues which likely contributes in
different capacities to the evolution of tissues injury. In the
present study, we found that when WT and PPAR-aKO
Figure 8 Effect of PPAR-a on the anti-inflammatory property of simvastatin on NF-B activation after SCI. Citoplasmatic IB-a and
nuclear p65 NF-B levels were detected in the spinal cord from sham and injured-PPAR-aKO mice and PPAR-aWT mice treated or not with
simvastatin. A basal level of IB-a was detected in the spinal cord tissues from sham WT mice (a) and from sham PPAR-a KO mice (a), whereas
IB-a levels were substantially reduced after SCI and significantly in PPAR-aKO mice (a). Simvastatin treatment, instead, increased IB-a levels in
both mice group but significantly more in WT treated mice (a). In addition, SCI caused a significant increase in nuclear NF-B p65 compared to
the sham-operated mice (b) and these increase was higher in SCI PPAR-aKO mice (b) than sham PPAR-aWT mice (b). Simvastatin treatment (10
mg/kg at 1 and 6 h after SCI induction) significantly reduced NF-B p65 levels much more in WT treated mice (b) than PPAR-aKO mice (b).
Polyclonal actin and lamin were used as internal control. The bars of each western blot are represented a densitometry analysis expressed as
mean ± S.E.M. of three different experiments. *P < 0.01 vs. sham; °P < 0.01 vs. SCI-WT group; #P < 0.01 vs. simvastatin-treated group.
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mice were treated with simvastatin a significant inhibition
of FasL activation was evaluated in WT but not in PPAR-
aKO mice.
Recent studies have also demonstrated ROS induce
apoptosis in an early and likely causal event that contri-
butes to the spinal cord motor neuron death [70] fol-
lowing SCI [71]. Apoptosis is an important mediator of
secondary damage after SCI, it incurs its affects through
at least two phases: an initial phase, in which apoptosis
accompanies necrosis in the degeneration of multiple
cell types and a later phase, which is predominantly
confined to white matter and involves oligodendrocytes
and microglia [72]. Chronologically, apoptosis initially
occurs 6 hours post-injury at the lesion centre and last
for several days associated with the steadily increased
number of apoptotic cells in this region. An important
intracellular signal transduction pathway that leads to
apoptosis after SCI involves activation of the caspases,
in particular, caspase-3 [73].
Has been demonstrated that PPAR-a suppress the apop-
tosis in hepatocytes [74], we have also recently demon-
strated that exogenous PPAR-a ligand inhibits apoptotic
cell death in spinal cord tissues from PPAR-aWT mice
subjected to SCI. In the present study, with immunohisto-
logical staining, we clearly demonstrate that WT mice
treatment with simvastatin induced a significant inhibition
of apoptotic process by reducing the expression of pro-
apoptotic gene like Bax and preventing the loss of anti-
apopoptotic gene Bcl-2. Notably, the absence of functional
PPAR-a receptor in PPAR-aKO mice inhibits the effect of
simvastatin treatment on the apoptotic process.
Moreover, previous studies showed that PPAR-a ago-
nists exert some anti-inflammatory activity [35,47].
Statins are competitive inhibitors of HMG-CoA reduc-
tase, the rate-limiting step in cholesterol synthesis thus
decreasing endogenous cholesterol synthesis. In addition
to their potent action on plasma lipid concentrations,
statins exert pleiotropic activities such as that antiplate-
let, antioxidant, anti-inflammatory and immunomodula-
tory [75,76]. Just for these pleiotropic effects statins are
considered a valid therapeutic approach for the different
and numerous pathways involved in the pathogenesis of
sepsis. In fact, clinical data obtained from retrospective
database and observational studies suggested that statins
may be helpful in sepsis [77].
Moreover a large and growing body of evidences also
suggest beneficial therapeutic activities of statins in
immune and inflammatory diseases such as multiple
sclerosis, Alzheimer’s disease, ischemic stroke, transplant
rejection, rheumatoid arthritis, and asthma [10,11].
The efficacy of simvastatin treatment in cardiovascu-
lar, inflammatory and autoimmune diseases is an impor-
tant therapeutic subject and while some patients obtain
clinical improvements from treatment, others are not
responsive or even resistant to therapy. The reasons of
response or not response to statin therapy are not fully
understood and molecular mechanisms.
Conclusions
In conclusion, results here discussed confirm a new
mechanism contributing to determine the full statin effi-
cacy and suggest future studies aimed to analyze the
possible relevance of PPAR-a in other human inflamma-
tory diseases such as SCI.
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